BioLight Life Sciences (BOLT) Stock Overview
Engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BOLT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BioLight Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪3.65 |
| 52 Week High | ₪6.37 |
| 52 Week Low | ₪2.09 |
| Beta | 0.56 |
| 1 Month Change | 25.74% |
| 3 Month Change | 35.15% |
| 1 Year Change | -33.62% |
| 3 Year Change | -44.03% |
| 5 Year Change | -69.79% |
| Change since IPO | -99.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOLT | IL Life Sciences | IL Market | |
|---|---|---|---|
| 7D | -6.5% | 6.8% | 4.6% |
| 1Y | -33.6% | 17.2% | 20.1% |
Return vs Industry: BOLT underperformed the IL Life Sciences industry which returned 17.2% over the past year.
Return vs Market: BOLT underperformed the IL Market which returned 20.1% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 14.6% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IL Market | 9.7% |
| 10% least volatile stocks in IL Market | 3.8% |
Stable Share Price: BOLT's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: BOLT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Yaacov Michlin | bio-light.co.il |
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx Dry Eye Syndrome; and Ocuvia, a front-to-back ocular treatment that includes ocudrip and ocugrid. It also provides Eye-D technology which treats glaucoma by the insertion of a sub-conjunctival implant; and Ocular D, a product for treating dryness in the eye with integrated vitamin D. In addition, the company engages in the development of drugs for treating eye diseases using a technological platform that enhances the transmission of active substances based on nanostructures.
BioLight Life Sciences Ltd. Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market cap | ₪33.13m |
| Earnings (TTM) | -₪11.73m |
| Revenue (TTM) | n/a |
Is BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪11.73m |
| Earnings | -₪11.73m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 01:43 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioLight Life Sciences Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |